EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY 4.0

Glucagon‐like peptide‐1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta‐analysis

Andrea Saglietto iD, Giulio Falasconi, Diego Penela, Pietro Francia, Arunashis Sau, Fu Siong Ng, Veronica Dusi, Davide Castagno, Fiorenzo Gaita, Antonio Berruezo, Gaetano Maria De Ferrari, Matteo Anselmino

European Journal of Clinical Investigation · 2024-12 · 54 (12)

DOI: 10.1111/eci.14292 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift European Journal of Clinical Investigation, online erschienen am 26.07.2024. Verfasst von Andrea Saglietto und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Cardiovascular and Thoracic Department, "Citta della Salute e della Scienza" Hospital, Turin, Italy. Hauptthemen laut MEDLINE: Atrial Fibrillation, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are new anti‐hyperglycaemic drugs with proven cardiovascular (CV) benefit in diabetic and non‐diabetic patients at high CV risk. Despite a neutral class effect on arrhythmia risk, data on semaglutide suggest a possible drug‐specific benefit in reducing atrial fibrillation (AF) occurrence.

Objective

To perform a meta‐analysis of randomized clinical trials (RCTs) to assess the risk of incident AF in patients treated with semaglutide compared to placebo. Methods and Results Ten RCTs were included in the analysis. Study population encompassed 12,651 patients (7285 in semaglutide and 5366 in placebo arms), with median follow‐up of 68 months. A random effect meta‐analytic model was adopted to pool relative risk (RR) of incident AF. Semaglutide reduces the risk of AF by 42% (RR .58, 95% CI .40–.85), with low heterogeneity across the studies ( I 2 0%). At subgroup analysis, no differences emerged between oral and subcutaneous administration (oral: RR .53, 95% CI .23–1.24, I 2 0%; subcutaneous: RR .59, 95% CI .39–.91, I 2 0%; p ‐value .83). In addition, meta‐regression analyses did not show any potential influence of baseline study covariates, in particular the proportion of diabetic patients ( p ‐value .14) and body mass index (BMI) ( p ‐value .60).

Conclusions

Semaglutide significantly reduces the occurrence of incident AF by 42% as compared to placebo in individuals at high CV risk, mainly affected by type 2 diabetes mellitus. This effect appears to be consistent independently of the route of administration of the drug (oral or subcutaneous), the presence of underlying diabetes and BMI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationDiabetes Mellitus, Type 2Glucagon-Like PeptidesRandomized Controlled Trials as TopicGlucagon-Like Peptide-1 Receptor AgonistsHumansAdministration, OralIncidenceInjections, SubcutaneousSemaglutide

Stichwörter der Autor:innen

atrial fibrillationglucagon‐like peptide‐1 receptor agonistsoverweightsemaglutide

Substanzen

Glucagon-Like PeptidesGlucagon-Like Peptide-1 Receptor AgonistsSemaglutide

Autor:innen und Institutionen

  • Division of Cardiology, Cardiovascular and Thoracic Department, "Citta della Salute e della Scienza" Hospital, Turin, Italy.
  • Department of Medical Sciences, University of Turin, Turin, Italy.
  • Heart Institute, Teknon Medical Centre, Barcelona, Spain.
  • Campus Clínic, University of Barcelona, Barcelona, Spain.
  • Arrhythmology Department, IRCCS Humanitas Research Hospital, Rozzano, Italy.
  • Division of Cardiology, Department of Clinical and Molecular Medicine, St. Andrea Hospital, Sapienza University.

ORCID-Profile: Andrea Saglietto

Zitieren

APA

Saglietto, A., Falasconi, G., Penela, D., Francia, P., Sau, A., Ng, F. S., Dusi, V., Castagno, D., Gaita, F., Berruezo, A., De Ferrari, G. M., & Anselmino, M. (2024). Glucagon‐like peptide‐1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta‐analysis. European Journal of Clinical Investigation, 54(12). https://doi.org/10.1111/eci.14292

Vancouver

Saglietto A, Falasconi G, Penela D, Francia P, Sau A, Ng FS, et al. Glucagon‐like peptide‐1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta‐analysis. European Journal of Clinical Investigation. 2024;54(12). doi:10.1111/eci.14292

BibTeX
@article{Saglietto2024,
  author = {Saglietto, Andrea and Falasconi, Giulio and Penela, Diego and Francia, Pietro and Sau, Arunashis and Ng, Fu Siong and Dusi, Veronica and Castagno, Davide and Gaita, Fiorenzo and Berruezo, Antonio and De Ferrari, Gaetano Maria and Anselmino, Matteo},
  title = {Glucagon‐like peptide‐1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta‐analysis},
  journal = {European Journal of Clinical Investigation},
  year = {2024},
  volume = {54},
  number = {12},
  doi = {10.1111/eci.14292}
}
Kostenlos starten →